All In Biotech

Drug Trial Radar · NCT01895309

A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

Last checked: Nov 20, 2026Latest source record: Aug 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 596 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

596

Actual

Start

Jun 2013

Primary completion

Apr 2014

Study completion Oct 2015

Sponsor

Lead sponsor
Samsung Bioepis Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 10, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, parallel group, multicentre clinical study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB4 compared to Enbrel in subjects with moderate to severe Rheumatoid Arthritis (RA) despite Methotrexate (MTX) therapy. In some countries, after 52 weeks of treatment with either SB4 or Enbrel, subjects will be enrolled into an open label extension period. Subjects will receive SB4 for an additional 48 weeks.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Enbrel (etanercept)Drug

  • SB4 (proposed biosimilar to etanercept)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. American College of Rheumatology 20% Response Criteria (ACR20)Time frame: Week 24

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Investigational Site

    Kielce, Poland

  • Investigational Site

    Southampton, Hampshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.